PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+2.15%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$843M
AUM Growth
+$843M
(+12%)
Cap. Flow
+$124M
Cap. Flow
% of AUM
14.72%
Top 10 Holdings %
Top 10 Hldgs %
33.86%
Holding
109
New
20
Increased
44
Reduced
26
Closed
18
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$22.7M |
| 2 |
CVS Health
CVS
|
$21.5M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
UnitedHealth
UNH
|
$15.8M |
| 5 |
Revvity
RVTY
|
$14.8M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$29.2M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$20.3M |
| 3 |
Abbott
ABT
|
$20M |
| 4 |
Gilead Sciences
GILD
|
$17.5M |
| 5 |
Boston Scientific
BSX
|
$11.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insulet
PODD
$23.9B
| $34.3M | 4.07% | 130,514 +4,753 | +4% | +$1.25M |
|
|
2
CVS Health
CVS
$92.8B
| $33.7M | 3.99% | 496,736 +316,736 | +176% | +$21.5M |
|
3
Eli Lilly
LLY
$657B
| $32.4M | 3.84% | 39,191 +11,028 | +39% | +$9.11M |
|
4
Stryker
SYK
$150B
| $28.9M | 3.43% | 77,690 -27 | -0% | -$10.1K |
|
5
Tenet Healthcare
THC
$16.3B
| $28.7M | 3.4% | 213,418 +106,431 | +99% | +$14.3M |
|
6
Becton Dickinson
BDX
$55.3B
| $27.6M | 3.27% | 120,283 +49,879 | +71% | +$11.4M |
|
7
Cooper Companies
COO
$13.4B
| $26.4M | 3.13% | 312,650 +38,081 | +14% | +$3.21M |
|
|
8
UnitedHealth
UNH
$281B
| $26.3M | 3.12% | 50,213 +30,213 | +151% | +$15.8M |
|
|
9
Gilead Sciences
GILD
$140B
| $24.5M | 2.91% | 218,950 -155,875 | -42% | -$17.5M |
|
|
10
Boston Scientific
BSX
$156B
| $22.8M | 2.7% | 225,990 -111,364 | -33% | -$11.2M |
|
|
11
Zimmer Biomet
ZBH
$21B
| $22.7M | 2.69% | +200,500 | New | +$22.7M |
|
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $19.6M | 2.32% | +277,252 | New | +$19.6M |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $18.6M | 2.21% | 168,382 +52,655 | +45% | +$5.82M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $18.6M | 2.21% | 68,938 +30,266 | +78% | +$8.17M |
|
15
Travere Therapeutics
TVTX
$1.56B
| $17.1M | 2.03% | 954,071 -163,721 | -15% | -$2.93M |
|
16
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $16.9M | 2.01% | 762,621 -2,832 | -0.4% | -$62.9K |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $16.5M | 1.96% | 260,421 -460,236 | -64% | -$29.2M |
|
18
RxSight
RXST
$370M
| $15.9M | 1.89% | 631,238 +330,540 | +110% | +$8.35M |
|
19
CVRx
CVRX
$205M
| $15M | 1.78% | 1,229,522 +308,348 | +33% | +$3.77M |
|
20
McKesson
MCK
$85.4B
| $14.9M | 1.76% | 22,101 -899 | -4% | -$605K |
|
|
21
Revvity
RVTY
$10.5B
| $14.8M | 1.75% | +139,557 | New | +$14.8M |
|
22
Edwards Lifesciences
EW
$47.8B
| $14.6M | 1.73% | 200,819 +55,605 | +38% | +$4.03M |
|
23
Qiagen
QGEN
$10.1B
| $14.4M | 1.71% | 359,644 +82,372 | +30% | +$3.31M |
|
24
Viridian Therapeutics
VRDN
$1.5B
| $14.3M | 1.7% | 1,064,506 -23,128 | -2% | -$312K |
|
25
PTC Therapeutics
PTCT
$3.92B
| $14.3M | 1.69% | 280,314 +102,946 | +58% | +$5.25M |
|